Sees 2H and FY24 positive adjusted free cash flow to exceed 50% of adjusted EBITDA, including full year interest expense of $160M-$165M and CapEx of ~$170M, excluding reagent rentals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QDEL:
- QuidelOrtho sees Q4 OpEx ‘relatively flat’ vs. Q3
- QuidelOrtho sees FY24 adjusted EBITDA $530M-$550M
- QuidelOrtho says China continues to be a ‘complex market’
- QuidelOrtho says ‘solid progress’ executing business improvement initiatives
- QuidelOrtho reports Q3 adjusted EPS 85c, consensus 32c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
